About us   Contacts   Links   Information in Russian 
Research programms
Publications

The list of publications in 2020


  1. Goswami P., Oliva E.N., Ionova T., et al. Quality-of-life issues and symptoms reported by patients living with haematological malignancy: a qualitative study. 2020. Ther Adv Hematol, Vol. 11: 114 (In Russ). DOI:/10.1177/2040620720955002.
  2. Goswami P., Oliva E.N., Ionova T., et al. Development of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Content Validity. Front. Pharmacol. 2020; 11: 209. doi:10.3389/fphar.2020.00209.
  3. Goswami P., Oliva E.N., Ionova T., et al. Reliability of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure: HM-PRO. Front. Pharmacol. 2020; 11: 571066. doi: 10.3389/fphar.2020.571066.
  4. Goswami P., Oliva E.N., Ionova T., et al. Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Construct Validity Study. Front. Pharmacol. 2020; 11: 1308. doi: 10. 3389/fphar.2020.01308.
  5. Morozova E.V., Barabanshchikova M.V., Ionova T.I., Afanasyev B.V. Attitudes to the disease and therapy in patients with chronic Ph-negative myeloproliferative neoplasms: results of the physician and patient surveys in Russia as a part of International Landmark Study. Cellular Therapy and transplantation. 2020; 9 (2): 2839.
  6. Ionova T.I., Vinogradova O.Yu., Efremova E.V., et al. Development and Validation Results of the Russian MPN10 Form for Symptom Assessment in Patients with Myeloproliferative Neoplasms in Compliance with International Recommendations. Clinical oncohematology. 2020; 13 (2): 17684 (In Russ). DOI: 10.21320/2500-2139-2020-13-2-176-184 (In Russ).
  7. Ionova T.I., Nikitina T.P., Mayevskaya E.A., et al. Development of the Russian version of quality of life questionnaire in patients with GERD GERD-HRQL. Therapeutic Archive. 2020; 92 (8): 1217 (In Russ). DOI: 10.26442/00403660.2020.08.000658.
  8. Ionova T.I., Zinkovskaya A.V., Mayevskaya E.A., et al. Testing and validation of the Russian version of quality of life questionnaire in patients with GERD GERD-HRQL. Therapeutic Archive. 2020; 92 (12): 5966 (In Russ). DOI: 10.26442/00403660.2020.12.200434.
  9. Ionova T.I., Bannikova A.Eu., Bykova A.V., et al. Development and psychometric evaluation of the specific questionnaire for quality of life assessment in patients with hematological malignancies in clinical practice HM-PRO. Bulletin of the Multinational Center for Quality of Life Research. 2020; 3536: . 86104 (In Russ).
  10. Nikitina T.P., Zherniakova A.A., Ionova T.I. The use of digital technologies for monitoring patient's quality of life in clinical practice and research. Bulletin of the Multinational Center for Quality of Life Research. 2020; 3536: . 1115 (In Russ).
  11. Ionova T.I., Lepik K.V., Mikhailova N.B., et al. Quality of life in patients with relapsed/refractory Hodgkin lymphoma receiving nivolumab in real clinical practice. Bulletin of the Multinational Center for Quality of Life Research. 2020; 3536: . 1632. (In Russ).
  12. Tsyba N.N, Ionova T.I, Lazareva O.V, et al. Quality of Life of Hematologists in the Russian Federation According to the RAND SF-36 Questionnaire. Clin ncohematology 2020; 13(4): 4119 (In Russ).
  13. Volkova A., Zinoveva M., Oleshko S., Kozlova T., Chernenko O. , Sviridova U., Gevorgian A., Paina O., Bikova T., Osipova A., Markova I., Semenova E., Potapchuk A., Ionova T., Nikitina T., Zubarovskaya L., Afanasyev B. The impact of medical and social rehabilitation on the quality of life in children with oncologic and hematologic diseases. EBMT 2020 Abstract Book; 2020; P.250.
  14. Fedorenko D., Melnichenko V., Zeinalov G., Ionova T. et al. Advances in multiple sclerosis (MS) treatment: clinical and patient-reported outcomes in patients undergoing autologous hematopoietic stem cell transplantation EBMT 2020 Abstract Book; 2020; 032.
  15. Ionova T., Ado E., Anchukova L., et al. Quality of Life (QoL) and Clinical Outcomes in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) receiving Ixazomib-Lenalidomide-Dexamethasone (IRd) in a real-world setting. Blood. 2020. 136 (Supplement 1): 2829. https://doi.org/10.1182/blood-2020-134415.
  16. Afanasyev B., Avtorhanova M., Bannikova A., Ionova T. et al. Implementation of Haematological Malignancies Patient-Reported Outcome Measure in Clinical Practice: Haematologists Experience. EMJ Hematology. 2020; Vol. 8 (1): 5961.
  17. Ionova T.I., Anchukova L.V., Dubov S.K., et al. Quality of Life and Response to Treatment with Ixazomib-Lenalidomide-Dexamethasone (IRd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in a real-world setting. Annals of Oncology. 2020; 31 (suppl_4): S590-S598. DOI:10.1016/annonc/annonc261.
  18. Afanasyev B., Avtorhanova M., Bannikova A., Ionova T. et al. Practical application of the HM-PRO in clinical practice: views from the trenches. Qual Life Res. 2020; 29: S112S113.
  19. Ionova T.I., Afanasyev B.V., Amdiev A.A., et al.. Response to therapy and quality of life in patients with refractory and recurrent Hodgkin's lymphoma treated with brentuximab vedotin in real clinical practice. Hematology and Transfusiology. 2020; 65 (1): 146147. (In Russ).
  20. Petrova A.N., Chelysheva E.Yu., Shuhov O.A., Ionova T.I., et al. Tyrosine kinase inhibitor therapy withdrawal syndrome in patients with chronic myeloid leukemia in a prospective observational clinical study in remission without treatment. Hematology and Transfusiology. 2020; 65 (1): 94. (In Russ).
  21. Tsyba N.N., Ionova T.I., Lazareva O.V., et al. Quality of life of hematologists in different regions of the Russian Federation. Hematology and Transfusiology. 2020; 65(1): 238239. (In Russ).
  22. Afanasyev B., Avtorhanova M., Bannikova A., Ionova T., et al. Implementation of Haematological Malignancies Patient-Reported Outcome Measure in Clinical Practice: Haematologists Experience. HemaSphere. 2020;Volume 4 (Issue S1): 125-126.
  23. Ionova T.I., Afanasyev B.V., Andrievskikh M.I., et al. Objective response rates and quality of life changes in patients with relapsed/refractory Hodgkin lymphoma (RR HL) receiving brentuximab vedotin as >2 line of treatment in the real world setting. HemaSphere. 2020;Volume 4 (Issue S1): 527528.
  24. Efremova E., Fominykh M., Ionova N., et al. The value of MPN10 to assess symptom burden in patients with myeloproliferative neoplasms. HemaSphere. 2020;Volume 4 (Issue S1): 969.








©

(last update): 03-10-2023